Regulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Update

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) was the target of a large decrease in short interest during the month of April. As of April 30th, there was short interest totalling 4,210,000 shares, a decrease of 32.9% from the April 15th total of 6,270,000 shares. Based on an average daily trading volume, of 3,040,000 shares, the short-interest ratio is presently 1.4 days. Approximately 7.3% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on RGLS shares. HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of Regulus Therapeutics in a research note on Monday, May 6th. Leerink Partnrs reissued an "outperform" rating on shares of Regulus Therapeutics in a research note on Monday, March 18th. Canaccord Genuity Group reduced their target price on shares of Regulus Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Tuesday, March 19th. StockNews.com started coverage on shares of Regulus Therapeutics in a research note on Tuesday, April 16th. They set a "sell" rating for the company. Finally, Wells Fargo & Company boosted their target price on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.25.

Regulus Therapeutics Stock Performance

Shares of NASDAQ:RGLS traded down $0.04 during trading on Friday, reaching $2.21. The company had a trading volume of 659,058 shares, compared to its average volume of 362,160. The firm's fifty day moving average is $2.38 and its 200 day moving average is $1.71. The firm has a market capitalization of $144.68 million, a PE ratio of -1.51 and a beta of 1.59. Regulus Therapeutics has a twelve month low of $1.08 and a twelve month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) EPS for the quarter, meeting the consensus estimate of ($0.40). Equities analysts predict that Regulus Therapeutics will post -0.52 earnings per share for the current fiscal year.

Institutional Trading of Regulus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in RGLS. Victory Capital Management Inc. lifted its stake in Regulus Therapeutics by 5.3% during the third quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company's stock valued at $322,000 after purchasing an additional 11,701 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Regulus Therapeutics by 158.4% during the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company's stock valued at $2,132,000 after acquiring an additional 453,784 shares during the period. FMR LLC raised its holdings in shares of Regulus Therapeutics by 32.4% during the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company's stock valued at $4,033,000 after acquiring an additional 716,000 shares during the period. CVI Holdings LLC acquired a new stake in shares of Regulus Therapeutics during the first quarter valued at approximately $4,050,000. Finally, Vivo Capital LLC acquired a new stake in shares of Regulus Therapeutics during the first quarter valued at approximately $14,400,000. 92.38% of the stock is owned by institutional investors and hedge funds.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.